Objective: To follow-up previous studies highlighting a possible role for cytochrome P450, family 2, subfamily C, 19 (CYP2C19) in susceptibility to endometriosis by searching for additional variants in the CYP2C19 gene that may be associated with the disease. Design: Case-control study. Setting: Academic research. Subject(s): The cases comprised 2,271 women with surgically confirmed endometriosis; the controls comprised 939 women with selfreport of no endometriosis and 1,770 unscreened population samples. Intervention(s): Sequencing of the CYP2C19 region and follow-up of 80 single nucleotide polymorphisms (SNPs) in two case-control samples. Main Outcome Measure(s): Allele frequency differences between cases and controls. Result(s): Sequencing of the CYP2C19 gene region resulted in the detection of a large number of known and novel SNPs. Genotyping of 80 polymorphic SNPs in 901 endometriosis cases and 939 controls resulted in study-wide significant association signals for SNPs in moderate or complete linkage disequilibrium with rs4244285, a functional SNP in exon 5 that abrogates CYP2C19 function through the creation of an alternative splice site. Evidence of association was also detected for another functional SNP in the CYP2C19 promoter, rs12248560, which was highlighted in our previous study. Conclusion (s): Functional variants in CYP2C19 may contribute to endometriosis susceptibility in both familial and sporadic cases. (Fertil Steril Ò 2014;102:496-502. Ó2014 by American Society for Reproductive Medicine.) Key Words: Endometriosis, association, pooled sequencing, CYP2C19, rs12248560, rs4244285
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E ndometriosis is a gynecological disease that affects 6%-10% of women of reproductive age and causes a variety of symptoms including severe menstrual pain, chronic pelvic pain, and subfertility (1) . The disease is inherited as a complex trait (1) (2) (3) , with up to 52% of the variation in liability accounted for by genetic factors (4) . Recent genome-wide association studies (GWAS) have revealed a number of common genetic variants associated with susceptibility to endometriosis (5) (6) (7) (8) . Both linkage and association studies take advantage of linkage disequilibrium (LD), where the alleles of single nucleotide polymorphisms (SNPs) located within short distances of each other are correlated. As has been the case in other complex diseases, the causal variants underlying endometriosis risk may be uncommon or novel SNPs in LD with the common markers genotyped in the original studies. Such SNPs can be detected by sequencing of regions surrounding association and linkage signals and may contribute more to disease risk in the population than the common variants originally detected (9) .
We recently fine-mapped a linkage peak for endometriosis on chromosome 10 (10), finding evidence suggestive of association with the cytochrome P450 family 2, subfamily C, 19 (CYP2C19) gene (11) . The CYP2C19 protein participates in the metabolism of estrogen (12, 13) and up to 10% of clinically administered medications (14) including the antiestrogenic drug tamoxifen (15) . The gene has a number of functional variants that influence drug metabolism, one of which, rs12248560, we found to be associated with endometriosis risk (11) . As this common SNP (minor allele frequency [MAF] ¼ 0.21) did not fully account for the linkage signal, it is possible that additional SNPs contribute to the endometriosis susceptibility associated with this chromosomal region. Interestingly, we also found nominal association with a SNP independent of rs12248560, rs4244285 (LD estimate r 2 ¼ 0.04), a loss-of-function variant in CYP2C19 exon 5 that had been previously associated with endometriosis risk in a small candidate gene study (16) , although this result was not replicated in an even smaller sample (17) .
The previously detected fine-mapping association signal extended across 252.3 kilobases (kb) of chromosome 10 from the 3' end of the helicase, lymphoid-specific (HELLS) gene to the 3' end of CYP2C19 (11) . This region includes another CYP2C gene family member, CYP2C18. In the current study, we aimed to search for additional variants in this region that may contribute to endometriosis risk. We screened endometriosis cases for such risk variants using two strategies. First, to search for variants that may have a direct effect on gene activity we screened the 5' and 3' untranslated regions (UTRs), exons and intron-exon boundaries of CYP2C18 and CYP2C19 in 20 unrelated endometriosis cases with a strong family history of disease. Next, to broaden the search to include intergenic and intronic regions that may harbor variants with regulatory effects on gene activity, we sequenced the entire 252.3 kb association region in DNA pools of 384 endometriosis cases and 384 controls. Casecontrol association analyses were then performed on a subset of the variants we detected by sequencing and provided further evidence that functional SNPs in CYP2C19 may contribute to endometriosis risk.
MATERIALS AND METHODS

Samples
Case samples were taken from the set of 3,908 endometriosis cases with and without a family history of disease recruited by the QIMR Berghofer Medical Research Institute between 1995 and 2002 (5). All women had completed a questionnaire and provided a blood sample. A surgical diagnosis was confirmed by retrospective examination of medical records; disease severity was determined using the revised American Fertility Society (rAFS) classification system (18) . Control samples comprised unrelated individuals originally recruited through QIMR Berghofer for either a twin study of gynecological health who self-reported no endometriosis (discovery sample) (4) or the sample previously used for our endometriosis GWAS (replication sample) (5) recruited through the Brisbane Adolescent Twin Study (19, 20) . Approval for this study and to obtain medical records, for collection of blood for DNA extraction and all questionnaires and interview schedules and for the inclusion of twin individuals recruited through the Australian Twin Registry, was obtained from the QIMR Berghofer Human Research Ethics Committee. All participants gave written informed consent.
Familial Sequencing
DNA samples from 20 unrelated women from 20 of the most case-dense endometriosis families included in our linkage study (10) were subjected to Sanger sequencing to search for potentially high-risk rare sequence variants contributing to endometriosis risk. Each family had three or more affected first-or second-degree relatives, with the sample chosen for sequencing having either the more severe disease (according to rAFS stages I-IV) (18) or the earliest age of onset if affected family members had been assigned the same stage.
Primers for the polymerase chain reaction (PCR) amplification and sequencing of the promoter and 3' UTR regions, intron-exon boundaries, and all exons of the CYP2C18 and CYP2C19 gene were designed using Primer 3.0 (21) (Supplemental Table 1 C for 10 minutes. Products were verified by electrophoresis through 2% agarose gels, cleaned with Exonuclease I and Shrimp Alkaline Phosphotase (Fermentas), and sequenced using BigDye 3.0 terminator chemistry (Applied Biosystems).
Pooled Sequencing of the HELLS-CYP2C19 Region DNA samples had previously been combined into two pools comprising 384 endometriosis cases (case pool) and 384 unrelated gynecological health study samples (control pool) (22) . Targeted resequencing and analysis of the case and control DNA pools were performed by deCODE Scientific Services. Briefly, for each pool, DNA within the $252.3-kb region extending from the 3' end of HELLS to the 3' end of CYP2C19 (covering chromosome 10 bases 96,361,710-96,704,010 [genome build GRCh37/hg19]) was amplified in sections by long-range PCR (average length, 8,021 bases) and sequenced on an Illumina GAIIx platform (Illumina). Short read sequences were then aligned, and sequence variants (SVs; termed as such as many loci were yet to be verified) were called by deCODE using the Illumina programs CASAVA and Elandv2. In addition, we reanalyzed the sequences using programs tailored for DNA pools: sequences were aligned using the program Novoalign (http://www.novocraft.com/ main/index.php), and SVs were called using CRISP (23) .
Individual Genotyping and Association Analyses
Genotyping of SVs detected by individual and pooled sequencing was conducted in a discovery sample of 958 endometriosis cases and 959 unrelated gynecological health study controls examined in previous genetic association studies for endometriosis conducted at QIMR Berghofer (24) (25) (26) (27) (28) (29) . This sample includes all 768 individuals (384 cases and 384 controls) included in the DNA pools described above. SVs were genotyped in multiplex assays using the Sequenom MassARRAY Genomics Platform (Sequenom (30) .
Genotyping quality control was performed for each multiplex separately, where SVs with >5% missing genotypes and Hardy-Weinberg P values <1 Â 10 À4 were excluded from further analyses. In addition, individuals missing >5% of data, or for whom we have recent genetic evidence of nonCaucasian ancestry detected during our GWAS analysis (5), were also removed. Single SNP and haplotype association analyses were performed including 901 of the 958 endometriosis cases and 939 of the 959 gynecological health study controls passing all quality control metrics using PLINK (31) . Studywide significance at the discovery phase (P adjusted < .05) was determined by 10,000 permutations of the data set, where case-control status was randomly swapped to break the genotype-phenotype relationship while preserving the LD structure between the SNPs, to generate empirical significance levels corrected for multiple testing resulting from the large number of SNPs included in the study.
Replication
As only Australian samples were genotyped in the discovery phase, we performed in silico replication on Australian cases and controls only, using a sample comprising 1,370 unrelated endometriosis cases and 1,770 unrelated Brisbane Adolescent Twin study controls drawn from our recent GWAS for endometriosis (5) . Briefly, all Australian GWAS individuals not included as, or related to, an individual from the 958 case sample were used as cases or controls for the replication sample. As the best SNPs from the discovery phase analysis were not present on the Illumina 610K genotyping chips used to genotype the GWAS samples, we analyzed genotype data and dosage scores for SNPs previously imputed to HapMap2 (32) . All imputed SNPs had genotype concordance values between 97.1% and 99.7% for 560 endometriosis cases for whom both actual and imputed genotypes were available, with imputation quality scores >0.9, indicating that these SNPs were imputed with a high degree of accuracy.
Association analyses were performed in the replication data set for three SNPs, rs1326837, rs4244285, and rs12248560, as described above. Since only associations in the same direction as in the discovery sample can be considered to be replicated, one-sided P values were obtained by halving the standard (two-sided) P values (8) . Unadjusted results obtained for both the discovery and replication sets were then included in a meta-analysis performed using METAL (8, 33) , which converts P values to Z-scores that are then weighted by the square root of the sample size for each sample set, to determine the total evidence of association for each SNP.
RESULTS
Sequencing Familial Endometriosis Cases
Sequencing of 20 cases from 20 unrelated case-dense endometriosis families for both the CYP2C18 and CYP2C19 genes revealed the presence of a number of known SNPs in addition to two novel intronic variants, one in intron 7 of CYP2C18 (chr10:96492949) and the second in intron 7 of CYP2C19 (chr10:96602941). As both SNPs were located at least 50 bases from the respective intron-exon boundaries, neither were predicted to have an effect on gene splicing (ESEfinder3.0: http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?proc ess¼home). A number of affected women carried the known functional CYP2C19 SNPs rs12248560 (CYP2C19*17, see http://www.cypalleles.ki.se/cyp2c19.htm for allele nomenclature) in the promoter region (associated with endometriosis risk in our previous fine-mapping study; (11)), rs17878459 (p.Glu92Asp: CYP2C19*3) in exon 2, and rs4244285 (p.Pro271Pro: CYP2C19*2) in exon 5.
Sequencing DNA Pools of Endometriosis Cases and Controls
Sequencing of the 252.3 kb between the end of the HELLS gene to the end of CYP2C19 in our two DNA pools of 384 endometriosis cases and 384 controls resulted in adequate sequence data (>500-fold coverage) for 96.8% and 94.0% of the region in each pool, respectively. Average sequence coverage was 1,261-fold for the case pool and 1,372-fold for the control pool. The largest gap of missing sequence ($20 kb) was in the region of 96.38-96.40 Mb for both pools (Supplemental Fig. 1 ).
DeCODE Genetics called 3,051 SVs using their analysis pipeline, of which 2,418 (79%) were novel (not present in SVs were instead more likely to be polymorphic if they were known SNPs (i.e., they had previously been assigned an ''rs'' number) and had been called by both variantcalling programs used in this study. Only 17/134 (12.7%) novel SVs were polymorphic in individual genotyping. Of the 63 known SNPs, 61 (97%) were polymorphic when individually genotyped, although these had pool MAFs within the range of the SVs shown to be monomorphic upon individual genotyping (0.001-0.5).
Fine-mapping Across the CYP2C19 Region
After quality control, 80 SNPs were polymorphic in the discovery sample of 901 endometriosis cases and 939 controls included in the association analysis. A nominal association signal (P%.05) was detected for 35 SNPs, 19 of which remained significant (P adjusted %.05) after permutation to correct for multiple testing (Table 2; Supplemental Table 2 ). Association signal was distributed across the sequenced region ( Fig. 1 The corresponding P value for the 19-SNP haplotype was 8.19 Â 10 À5 , and there was no evidence of an independent effect for rs1326837. These 19 SNPs include rs4244285, representing the subgroup of SNPs in moderate LD with rs1326837, which achieved an unadjusted P¼9.2 Â 10 À4 (P adjusted ¼2.5 Â 10 À2 ) and retained an unadjusted P¼2.7 Â 10 À2 in the conditional analyses.
The association signal for both rs1326837 and rs4244285 was replicated in the independent data set of 1,370 mostly nonfamilial endometriosis cases and 1,770 population controls, with a one-sided P value for rs1326837 of 3.1 Â 10
À3
(OR ¼ 1.19) and for rs4244285 of P¼8.0 Â 10 À3 (OR ¼ 1.18). Meta-analysis of the discovery and replication data sets produced a combined P value for rs1326837 of 1.3 Â 10 À6 and for rs4244285 of 9.4 Â 10
À5
, surpassing our threshold of total study-wide significance calculated as 6.2 Â 10 À4 (where P¼ .05/80 SNPs).
Evidence of association was also detected for rs12248560 (P¼6.4 Â 10 À3 , OR ¼ 0.80), the functional promoter SNP highlighted in our previous fine-mapping study (Table 2;  Supplemental Table 2 ). LD between rs12248560 and SNPs of the rs1326837 haplotype is low (average r 2 ¼ 0.04), hence the association signal was not affected by the conditional analysis described above, indicating that this SNP represents an independent effect on endometriosis risk. However, rs12248560 was no longer significant after permutation of the 901 case and 939 controls data set, indicating the signal for this SNP was not study-wide significant in the discovery set (P adjusted ¼ .16). However, there was evidence of association in the replication sample (one-sided P¼2.5 Â 10 À2 ; OR ¼ 0.88), and meta-analysis of the unadjusted discovery and replication data sets produced a combined P value for rs12248560 of 5.8 Â 10 À4 , indicating that this SNP is significant over the total study sample.
DISCUSSION
We have found genetic variants in the CYP2C19 gene to be associated with susceptibility to endometriosis among women with and without a family history of the disease. Previously, we found the rs12248560 functional promoter SNP to be associated with a decreased risk of endometriosis after our initial fine-mapping of a linkage peak on chromosome 10 (11). While it is study-wide significant, the rs12248560 signal is somewhat reduced in the current study (fine-mapping sample minor allele P¼4.9 Â 10 À4 ; OR ¼ 0.78 [11] vs. current discovery sample P¼6.4 Â 10 À3 , OR ¼ 0.80); this appears to be mostly due to the smaller sample size as only Australian cases and controls were included here. Although the effect of rs12248560 on gene transcription requires clarification (CYP2C19*17 was initially suggested to cause an ultrarapid drug metabolizer phenotype, but this has recently been questioned; [34] ), this SNP has also been associated with a decreased risk of breast cancer, particularly in women treated with hormone replacement therapy for 10 years or more (35) , indicating that functional CYP2C19 variants can influence the risk of estrogen-dependent conditions.
The finding of additional independent association signals provides evidence for the possibility that multiple variants contributed to the original linkage peak in this region (10) . Of particular interest is the top SNP from this study, rs1326837. Located in the intergenic region between HELLS and CYP2C18, there is currently no evidence for a regulatory role for this particular SNP. However, previous GWAS to find variants influencing pharmacological drug response have detected SNPs in this intergenic region (e.g., rs12772169 and rs12777823) that are in complete and moderate LD with rs1326837 and are also linked to functional SNPs in various CYP2C genes (36, 37) . Such SNPs may be contributing to the risk of endometriosis detected here.
SNPs in moderate LD with rs1326837 include the functional SNP rs4244285 (r 2 ¼ 0.64). This synonymous SNP in CYP2C19 exon 5 causes no change to the amino acid (p.Pro227Pro) but creates an alternative splice site 40 bases downstream, resulting in a truncated, nonfunctional protein (38) and a poor metabolizer phenotype (CYP2C19*2). In our previous fine-mapping study including cases from Australia and the United Kingdom, we found only nominal association with rs4244285 (OR ¼ 1.23, P¼1.1 Â 10 À2 ) in 1,158 familial and sporadic cases (11) , indicating that association with this SNP was not driving the association signal detected in that sample. Given that the signal for rs4244285 is more significant in the current study (discovery sample OR ¼ 1.35, P¼9.7 Â 10 À4 ; meta-analysis OR ¼ 1.35, P¼9.4 Â 10 À5 ),
FIGURE 1
Association signal across the 252.3-kb region between the HELLS and CYP2C19 genes on chromosome 10. The genomic positions of the top SNP rs1326837 and the two functional SNPs rs4244285 and rs12248560 are indicated by dashes next to the SNP names.
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despite the smaller sample size, this may indicate that the effect of this SNP on endometriosis risk is larger in the Australian than in the United Kingdom population. CYP2C19 participates in the conversion of 17b-estradiol (E 2 ) to estrone (E 1 ) (12) and in the production of 2a-hydroxy estrogen (2a-OHE) (12, 13) . This gene may exert its disease risk altering-effects through two mechanisms, either independently or in concert. That SNPs causing the increased metabolizer phenotypes (rs12248560) are protective, while SNPs causing the poor metabolizer phenotype (rs4244285) increase the risk of disease, supports the hypothesis that CYP2C19 SNPs may alter endometriosis risk through an effect on local and/or central estrogen metabolism. Altered CYP2C19 activity may affect localized, tissue-specific rates of conversion of E 2 to E 1 and/or result in altered levels of the antiestrogenic 2a-OHE metabolite, with activity either increased or decreased as compared with the wild-type isoform depending on the true causal variant(s). Evidence for the role of other genes involved in sex-steroid metabolism in endometriosis is currently equivocal at best, owing mostly to the small sample sizes that are typically analyzed in candidate gene studies (39, 40) .
Alternatively, CYP2C19 may affect endometriosis risk through altered metabolism of exogenous substances, which may increase the risk of developing this disease (41, 42) . CYP2C19 expression and activity is altered in response to xenobiotic as well as steroid hormone exposure (43, 44) . As seen for drug metabolism, it may be that CYP2C19 SNPs influence the rates at which other substances metabolized by this gene are cleared, either by the liver or locally at extrahepatic sites, and this may moderate endometriosis risk. As the use of plastics and associated chemicals has increased over the past decades (45), we examined effect sizes for rs12248560 and rs4244285 by period of endometriosis diagnosis among our cases (pre-and from 1994, the median year of diagnosis in our sample), and while larger effects were seen for both SNPs for cases diagnosed from 1994, these results were not significantly different (Supplemental Table 3 ).
In this study we sought to detect rare and possibly novel sequence variants associated with an increased risk of developing endometriosis through DNA sequencing of women with a family history and subsequent association analyses including case samples with and without a family history of disease. Instead, the best association signals detected were for common variants linked to known functional SNPs in the CYP2C19 gene. The effect sizes of these CYP2C19 variants are small but similar to variants associated with endometriosis in recent GWAS conducted by us (5) and others (6, 7). Although our current results are not significant at a genome-wide level, they are significant at a study-wide level and replicated in a large independent sample. Further studies to validate our findings in additional case and control data sets or functional experiments such as determining the association of SNPs with gene expression in relevant tissues will help to clarify the role of CYP2C19 in estrogen-dependent diseases. CYP2C19 is an important candidate owing to its role in the metabolism of estrogen and possibly also other substances that might be associated with the risk of developing endometriosis, and our study indicates that multiple SNPs in this gene region likely contribute to this risk. We also thank the many hospital directors and staff, gynecologists, general practitioners, and pathology services in Australia who provided assistance with confirmation of diagnoses and blood collection and Sullivan Nicolaides and Queensland Medical Laboratory for pro bono collection and delivery of blood samples.
SUPPLEMENTAL FIGURE 1
Sequence coverage in the (A) endometriosis case and (B) control DNA pools, scaled to 10,000-fold coverage. Note: Numbers refer to the amplicon (exonic primer names refer to the respective exon amplified). P ¼ promoter region primer; E ¼ exonic primer; F ¼ forward primer; R ¼ reverse primer. Note: Our endometriosis cases were diagnosed between 1965 and 2002, corresponding to a period during which potential exposure to environmental contaminants that may increase endometriosis risk (33) may have increased through, for instance, greater use of plastics and associated chemicals (34) . CI ¼ confidence interval. a Cases were divided into two groups by the median year of diagnosis in our data set, 1994, corresponding to a period after which exposure to environmental toxins as measured by bis-phenol- The significance between the effects of each SNP on endometriosis and the 2 years of diagnosis groups were tested by polytomous logistic regression (in STATA), appropriate for analyses comparing different sets of cases and the same set of controls.
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